TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients who have undergone surgical extraction of 3 or more third molars, of which at least 2 must be a partial or complete bony mandibular impaction.~* Subject must have at least moderate pain on the 4-point categorical scale, confirmed by at least 50 mm on the 100 mm VAS PSR scale within approximately 5 hours (i.e., less than or equal to 5 hours, 15 minutes) after surgery is completed.~* Female subjects are not pregnant or breast feeding.~* Informed consent.~Exclusion Criteria:~* Presence or history of any significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorder determined by the Investigator to place the subject at increased risk, including the presence or history within 2 years of screening.~* Acute localized dental alveolar infection at the time of surgery that could confound the post-surgical evaluation.~* Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID; or to APAP, tramadol, other opioids, or to their combinations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen 250 mg / Acetaminophen 500 mg (Type: EXPERIMENTAL): 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
- Ibuprofen 250 mg (Type: ACTIVE_COMPARATOR): 2 caplets of IBU 125 mg
- Acetaminophen 650 mg (Type: ACTIVE_COMPARATOR): 2 tablets of APAP 325 mg
- Placebo (Type: ACTIVE_COMPARATOR): 2 caplets of Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Women With an Incomplete Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation.~2. No known allergy to misoprostol.~3. Women who will be haemodynamically stable.~4. Good access to emergency facilities. Exclusion~1. Women with signs of severe infection ( fever \> 38°) 2. Women with severe vaginal bleeding 3. Women known to have allergy to prostaglandins 4. Severe abdominal pain requiring immediate intervention

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol group (Type: OTHER): The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
- Expectant group (Type: NO_INTERVENTION): Women did not receive any medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, age \>/=18 years~* Diagnosis of chronic renal anemia~* Not on dialysis~* Hemoglobin concentration \<10 g/dl~* No erythropoiesis stimulating agent (ESA) therapy during the 3 months before study start~* Estimated glomerular filtration rate (EGFR) \<60 ml/min and \>/=20 ml/min~* Adequate iron status~Exclusion Criteria:~* Transfusion of red blood cells during the previous 2 months~* Poorly controlled hypertension~* Significant acute or chronic bleeding, e.g. gastrointestinal bleeding~* Active malignant disease (except non-melanoma skin cancer)~* Hemolysis~* Hemoglobinopathies, e.g. sickle-cell disease, thalassemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels Correlated With Exercise

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women~* Aged 18 to 35 years old,~* Body mass index (BMI) \<30 kg/m2~* Without contraindication for exercising~Exclusion Criteria:~* Metabolic syndrome~* Diabetes~* Dyslipidemia~* Hypertension~* Asthma~* Thyroid disease~* Treated with fibrates, beta agonists or blockers~* History or current arrhythmias, murmurs, cardiomegaly, or treatment for cardiovascular diseases -~* Contraindications for exercise testing were also considered as exclusion criteria (see references)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Supervised exercising (Type: EXPERIMENTAL): A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)~* The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study~* Patients with diabetes mellitus requiring insulin therapy for whom the physician has decided to start treatment with Ryzodeg®~* Male or female, no age limitation~Exclusion Criteria:~* Patients who are or have previously been treated with Ryzodeg®~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Patients with a history of hypersensitivity to study product components~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- insulin degludec/insulin aspart (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preclinical HCM (identified sarcomere mutation with no clinical evidence of left ventricular hypertrophy)~* Able to provide informed consent (or parental consent)~Exclusion Criteria:~* Contraindication to diltiazem administration~* Impaired hepatic or renal function~* Age \< 5 years~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- I- Diltiazem (Type: EXPERIMENTAL): Diltiazem- study medication
- II- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CD20 and CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.~* Prior therapy must have contained at least one dose of Rituximab therapy. Patients can not be refractory to Rituximab (refractory = PD under treatment or within 6 month~* Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.~* Patients must not have received previous radioimmunotherapy.~* Patients tolerant to Rituximab.~* Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before first dose of test article.~Exclusion Criteria:~* Candidate for potentially curative therapies~* Subjects must not have received previous radioimmunotherapy.~* Subjects with autologous hematopoietic stem cell transplant within the last 6 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Inotuzumab Ozogamicin + Rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor in Primigravidas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Primigravidas.~  * Full term patients with ultrasound confirmed dates.~ * Singleton.~ * Cephalic presentation.~ * Fetal heart rate between 120 to 160 beats per minute.~Exclusion Criteria:~* • Any history of previous surgery on the uterus.~  * Patients in active labour, with ruptured membranes.~ * Fetal distress.~ * Macrosomia or polyhydramnios~ * Hypersensitivity to prostaglandins.~ * Asthmatic patient .~ * liver or kidney impairment .~ * known cardiac patient with abnormal ECG.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Misoprostol + propranolol (Type: ACTIVE_COMPARATOR): Patient who receive misoprostol then after 30minutes receive propranolol
- Misoprostol + placebo (Type: PLACEBO_COMPARATOR): Pt who will receive misoprostol then after 30minutes receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nefopam on Acute Postoperative Pain in Patients Undergoing Orthognathic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* aged 20-60 years~* undergoing elective orthognathic surgery~Exclusion Criteria:~* pregnancy~* psychiatric disease~* hepatobiliary or renal disease~* monoamine oxidase inhibitor-taking patients

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAPB vs QLBII for Kidney Transplantation Procedure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplantation procedure with anatomical urinary outlet~2. Written informed consent~Exclusion Criteria:~1. Patients' refusal~2. Known allergies to study medication~3. Inability to comprehend or participate in pain scoring scale~4. Inability to use intravenous patient controlled analgesia system~5. Anatomic, posttraumatic and postoperative deformations could possibly affect the spread of local anesthetic in transversus abdominalis plane or quadratus lumborum muscle plane.~6. Transversus abdominalis plane or quadratus lumborum muscle plane not seen in ultrasound examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quadratus Lumborum Block type II (Type: EXPERIMENTAL): Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
- Transversus Abdominalis Plane Block (Type: ACTIVE_COMPARATOR): Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the core study Screening Visit.~* Satisfactory completion of the core study in the opinion of the investigator and the sponsor.~* Subjects who are \>18 to ≤35 years of age at the time of screening and did not participate in one of the core studies may be eligible for participation.~* A documented medical history to support a clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.~* Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.~* Subject's parent/caregiver has been compliant with diary completion during the core study, in the opinion of the investigator (eg, at least 90% compliant).~Key Exclusion Criteria:~* Current or past history of cardiovascular or cerebrovascular disease, myocardial infarction or stroke.~* Current cardiac valvulopathy or pulmonary hypertension that is clinically significant and warrants discontinuation of study medication.~* Current or past history of glaucoma.~* Moderate or severe hepatic impairment.~* Receiving concomitant therapy with: centrally-acting anorectic agents; monoamineoxidase inhibitors; any centrally-acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; atomoxetine, or other centrally-acting noradrenergic agonist; cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates.~* Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as maintenance therapy.~* A clinically significant condition, or has had clinically relevant symptoms or a clinically significant illness at Visit 1, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ZX008 (Type: EXPERIMENTAL): ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Is a healthy male or female (to be confirmed by medical history);~* Is 18 years of age or older;~* In the case of a female of childbearing potential, is using two acceptable forms of birth control;~* In the case of a female of childbearing potential, has a negative urine pregnancy test (UPT) on Day 1 prior to randomization and are willing to submit to a UPT at the end of study (EOS);~* Is free of any systemic or dermatological disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs;~* Is of any Fitzpatrick Skin Type or race, providing the skin pigmentation will allow discernment of erythema~Key Exclusion Criteria:~* Has any visible skin disease at the application site which, in the opinion of the Investigator, will interfere with the evaluation of the test site reaction;~* Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;~* Is not willing to refrain from using systemic/topical anti-inflammatory analgesics such as aspirin, (occasional use of acetaminophen will be permitted);~* Is using medication which, in the opinion of the Investigator, will interfere with the study results;~* Is unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study;~* Has psoriasis and/or active atopic dermatitis/eczema;~* Has a known sensitivity or allergy to constituents of the materials being evaluated including diacerein, mineral oil, petrolatum, cetyl alcohol, D\&C Yellow #10 and/or ethyl paraben;~* Has damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;~* Has received treatment for any type of internal cancer within 5 years prior to study entry;~* Has any known sensitivity to adhesives; and/or~* Has received any investigational drug(s) within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- study in healthy volunteers (Type: OTHER): diacerein 1% ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Undergone elective total hip or knee replacement surgery~* Received postoperative venous blood clot prevention therapy within 24 hours of the surgery~* Currently prescribed enoxaparin 30mg subcutaneous (SQ) twice a day or 40mg SQ daily for venous blood clotting prevention with an expected duration of continued prevention therapy of at least 3 days after admission to a subacute unit~* Discharged from the hospital to a subacute unit (including skilled nursing facilities and rehabilitation units) and committed to remaining in the unit for the duration of the Pharmacodynamic blood sampling period of the study~Exclusion Criteria:~* Platelet count \<90,000/µL based on screening laboratory assessments~* active internal bleeding or high risk of bleeding~* history of, or condition associated with, increased bleeding risk including~* planned invasive procedure with potential for uncontrolled bleeding, including major surgery~* sustained uncontrolled high blood pressure, defined as systolic blood pressure =180 mmHg or diastolic blood pressure =100 mmHg~* clinically significant kidney disease and/or impaired kidney function~* clinically significant liver disease~* anemia~* known allergies, hypersensitivity, or intolerance to rivaroxaban~* indication for anticoagulant (blood thinning) therapy for a condition other than blood clot prevention~* anticipated need for treatment with a prescription or nonprescription non-steroidal anti-inflammatory drugs (NSAIDs)~* any patient who has taken more than one or two doses of aspirin (\>100 mg/dose) in the week prior to enrollment will not be allowed to participate~* Drug addiction or alcohol abuse within 3 years prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Pediatric patients who are diagnosed of having varicella and are presenting varicella dermal lesions.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Varicella Group (Type: EXPERIMENTAL): Subjects aged between 0 and 16 years of age, with clinically-diagnosed primary varicella disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete